TAK-960

TargetMol
Product Code: TAR-T7200
Supplier: TargetMol
CodeSizePrice
TAR-T7200-1mg1mg£117.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7200-2mg2mg£136.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7200-5mg5mg£169.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7200-1mL1 mL * 10 mM (in DMSO)£209.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7200-10mg10mg£209.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7200-25mg25mg£319.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7200-50mg50mg£484.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7200-100mg100mg£670.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
TAK-960 is an orally bioavailable, selective inhibitor of Plks with IC50 values of 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively.
CAS:
1137868-52-0
Formula:
C27H34F3N7O3
Molecular Weight:
561.61
Pathway:
Cell Cycle/Checkpoint
Purity:
0.98
SMILES:
COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1
Target:
PLK

References

Nie Z , Feher V , Natala S , et al. Discovery of TAK-960: An orally available small molecule inhibitor of polo-like kinase 1 (PLK1).[J]. Bioorganic & Medicinal Chemistry Letters, 2013, 23(12):3662-3666. Klauck P J , Bagby S M , Capasso A , et al. Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer[J]. BMC Cancer, 2018, 18(1):136. Hikichi Y, Honda K, Hikami K,et al.TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens[J].Mol Cancer Ther. 2012 Mar;11(3):700-9.